Kinfo
Context Therapeutics Inc. logo

Context Therapeutics Inc.

CNTXNASDAQHealthcare·US · USD
$0.47
+0.00 (+0.84%)
Prices as of August 12, 2026 · market closed

Price

Key statistics

Valuation
Market cap43.10M USD
Enterprise value51.94K USD
Trailing P/E-1.23
Forward P/E-1.13
PEG ratio-0.02
Price / sales0.00
Price / book1.12
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-45.70%
Return on equity-76.14%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-48.71M USD
Net income-45.96M USD
Diluted EPS-$0.49
Rev. growth (YoY)0.00%
Balance sheet
Total cash42.99M USD
Total debt244.99K USD
Debt / equity0.64
Current ratio5.81
Book value / share$0.42
Cash flow (TTM)
Operating cash flow-33.97M USD
Levered free cash flow-31.53M USD
Shares & price
Shares outstanding91.88M
Float44.94M
Held by institutions87.84%
Beta1.75
50-day MA$0.85
200-day MA$1.70
52-week high$3.62
52-week low$0.43
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-05-0.09-0.15−66.67%2026-05-06-0.12-0.09+25.00%2026-03-23-0.11-0.14−27.27%2026-02-16-10.85-0.59+94.56%2025-12-030.270.45+66.67%
About Context Therapeutics Inc.

Context Therapeutics Inc. is a biopharmaceutical company focused on advancing treatments for hormone-driven female cancers. Primarily, the company develops investigational therapies targeting estrogen receptors, aiming to innovate in areas of significant unmet medical need. Context Therapeutics operates within the life sciences and biotechnology sectors, engaging in research and development to combat cancers like breast and ovarian cancer. The company's approach involves optimizing therapeutic outcomes through cutting-edge research, clinical trials, and strategic collaborations. With a strong commitment to patient-centered care, Context Therapeutics impacts the healthcare industry by striving to provide more effective and personalized treatment options for female cancer patients. Established in an era of increased focus on women's health, Context Therapeutics plays a vital role in the continued evolution and enhancement of oncology treatment solutions in the financial market.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Martin A. Lehr
Employees
12
Headquarters
Philadelphia, PA, United States

Frequently asked questions about Context Therapeutics Inc.